Market Cap 2.61B
Revenue (ttm) 1.04M
Net Income (ttm) -298.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28,693.27%
Debt to Equity Ratio 0.00
Volume 891,900
Avg Vol 758,366
Day's Range N/A - N/A
Shares Out 93.63M
Stochastic %K 2%
Beta 0.33
Analysts Strong Sell
Price Target $70.60

Company Profile

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant,...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 450 6464
Address:
6055 Lusk Boulevard, San Diego, United States
Christyalmond
Christyalmond Aug. 1 at 7:14 PM
0 · Reply
ZManicItalian
ZManicItalian Jul. 31 at 5:06 PM
$CRNX added a few puts to hedge. This is acting like it wants to sell the approval and commercial rollout. I've been burned too many times to not hedge a bit 😬
0 · Reply
outlawinvestor1
outlawinvestor1 Jul. 27 at 5:49 PM
$CRNX nice overview on twitter. https://x.com/BalaBioResearch/status/1941197728106807621
0 · Reply
Japanesee
Japanesee Jul. 25 at 5:58 AM
0 · Reply
ZManicItalian
ZManicItalian Jul. 24 at 5:45 PM
$CRNX added some more $35 calls expiring January 🤞
1 · Reply
justiceforb_85
justiceforb_85 Jul. 24 at 1:42 AM
$CRNX anticipating positive movement headed into PDUFA for paltusotine which would be the first approved oral therapy for acromegaly versus current SoC using injections with side effects.
0 · Reply
Quantumup
Quantumup Jul. 23 at 3:47 PM
Cantor reiterated $NBIX Overweight/$170. W/ $NBIX reporting 2Q25 next Thurs—Cantor notes volatility around earnings (both⬆️&⬇️; avg 6%), over the last few yrs—but points to the last 3 years, 75% of $NBIX earning prints have seen shares trade higher. $CRNX $BMY $TEVA $PTCT Cantor said in its note: " $NBIX reports 2Q25 next Thursday - shares tend to be volatile around earnings, with avg moves of~6% (either up or down) over the past few years. While we generally feel good about Crenessity (high confidence) and Ingrezza (low/medium confidence), we note that the volatility and imprecision predicting quarterly earnings results for $NBIX keeps us on our toes. Each of the last 4 earnings reports have seen stock moves over 5% (either direction). Over the last 3 years, 75% of $NBIX earning prints have seen shares trade higher, so at least the earnings odds are favorable. 1Q25 saw an 8% bounce in shares after the -18% move down in 4Q24 (due to disappointing '25 guidance)."
0 · Reply
Quantumup
Quantumup Jul. 22 at 6:44 PM
Piper Sandler y'day reiterated $CRNX Overweight-$97-Top Pick after🗣️w/ a Leading ENDO—he Tx's a couple hundred acromegaly pts—plans to offer PALSONIFY immediately to almost all pts— +was impressed w/ atumelnant's Ph1b/2a Cushing's data/is +VE on this opp $BCHMY $IPSEY $NVS $CORT $XERS Piper Sandler in its note to investors said:
1 · Reply
RunnerSignals
RunnerSignals Jul. 22 at 3:12 AM
Analyst upside watch $MSTR $NET $CLF $IQV $CRNX all flashing near-term setups https://stocksrunner.com/news/2025-07-21-best-short-term-stocks-to-buy-now-with-strong-analyst-upside-potential
0 · Reply
Quantumup
Quantumup Jul. 21 at 5:39 PM
H.C. Wainwright reit'd $CRNX Buy-$81 &said, "At the #ENDO 2025 conference, we felt strong enthusiasm towards Palsonify (paltusotine) from many expert endocrinologists." $BCHMY $IPSEY $NVS #ENDO2025 H.C. Wainwright added, "They were all excited about the drug's compelling efficacy and durability on top of a convenient once-daily dosing regimen. Many called it a "game changer" in acromegaly compared to the current standard-of-care, whether intramuscular somatostatin receptor ligands (SRL) injections or twice-daily oral SRLs. Unlike the injectables, paltusotine has been shown to provide consistent biochemical and symptom control and reduce breakthrough symptoms. Its once-daily dosing allows patients to take it at bedtime without having to worry about fasting and food effects that are challenges with the twice-daily oral SRLs. The endocrinologists we spoke to all expected most of their acromegaly patients to switch to paltusotine. We reiterate our Buy and our price target of $81 for Crinetics."
0 · Reply
Latest News on CRNX
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

Jun 16, 2025, 8:00 AM EDT - 6 weeks ago

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025


Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D.

May 30, 2024, 4:05 PM EDT - 1 year ago

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D.


Christyalmond
Christyalmond Aug. 1 at 7:14 PM
0 · Reply
ZManicItalian
ZManicItalian Jul. 31 at 5:06 PM
$CRNX added a few puts to hedge. This is acting like it wants to sell the approval and commercial rollout. I've been burned too many times to not hedge a bit 😬
0 · Reply
outlawinvestor1
outlawinvestor1 Jul. 27 at 5:49 PM
$CRNX nice overview on twitter. https://x.com/BalaBioResearch/status/1941197728106807621
0 · Reply
Japanesee
Japanesee Jul. 25 at 5:58 AM
0 · Reply
ZManicItalian
ZManicItalian Jul. 24 at 5:45 PM
$CRNX added some more $35 calls expiring January 🤞
1 · Reply
justiceforb_85
justiceforb_85 Jul. 24 at 1:42 AM
$CRNX anticipating positive movement headed into PDUFA for paltusotine which would be the first approved oral therapy for acromegaly versus current SoC using injections with side effects.
0 · Reply
Quantumup
Quantumup Jul. 23 at 3:47 PM
Cantor reiterated $NBIX Overweight/$170. W/ $NBIX reporting 2Q25 next Thurs—Cantor notes volatility around earnings (both⬆️&⬇️; avg 6%), over the last few yrs—but points to the last 3 years, 75% of $NBIX earning prints have seen shares trade higher. $CRNX $BMY $TEVA $PTCT Cantor said in its note: " $NBIX reports 2Q25 next Thursday - shares tend to be volatile around earnings, with avg moves of~6% (either up or down) over the past few years. While we generally feel good about Crenessity (high confidence) and Ingrezza (low/medium confidence), we note that the volatility and imprecision predicting quarterly earnings results for $NBIX keeps us on our toes. Each of the last 4 earnings reports have seen stock moves over 5% (either direction). Over the last 3 years, 75% of $NBIX earning prints have seen shares trade higher, so at least the earnings odds are favorable. 1Q25 saw an 8% bounce in shares after the -18% move down in 4Q24 (due to disappointing '25 guidance)."
0 · Reply
Quantumup
Quantumup Jul. 22 at 6:44 PM
Piper Sandler y'day reiterated $CRNX Overweight-$97-Top Pick after🗣️w/ a Leading ENDO—he Tx's a couple hundred acromegaly pts—plans to offer PALSONIFY immediately to almost all pts— +was impressed w/ atumelnant's Ph1b/2a Cushing's data/is +VE on this opp $BCHMY $IPSEY $NVS $CORT $XERS Piper Sandler in its note to investors said:
1 · Reply
RunnerSignals
RunnerSignals Jul. 22 at 3:12 AM
Analyst upside watch $MSTR $NET $CLF $IQV $CRNX all flashing near-term setups https://stocksrunner.com/news/2025-07-21-best-short-term-stocks-to-buy-now-with-strong-analyst-upside-potential
0 · Reply
Quantumup
Quantumup Jul. 21 at 5:39 PM
H.C. Wainwright reit'd $CRNX Buy-$81 &said, "At the #ENDO 2025 conference, we felt strong enthusiasm towards Palsonify (paltusotine) from many expert endocrinologists." $BCHMY $IPSEY $NVS #ENDO2025 H.C. Wainwright added, "They were all excited about the drug's compelling efficacy and durability on top of a convenient once-daily dosing regimen. Many called it a "game changer" in acromegaly compared to the current standard-of-care, whether intramuscular somatostatin receptor ligands (SRL) injections or twice-daily oral SRLs. Unlike the injectables, paltusotine has been shown to provide consistent biochemical and symptom control and reduce breakthrough symptoms. Its once-daily dosing allows patients to take it at bedtime without having to worry about fasting and food effects that are challenges with the twice-daily oral SRLs. The endocrinologists we spoke to all expected most of their acromegaly patients to switch to paltusotine. We reiterate our Buy and our price target of $81 for Crinetics."
0 · Reply
ZManicItalian
ZManicItalian Jul. 17 at 1:40 PM
$CRNX run into approval!
0 · Reply
Quantumup
Quantumup Jul. 15 at 12:46 PM
Citizens reit'd $CRNX Mkt OP-$90 and said, " $CRNX presented new long-term safety and efficacy data from its open-label extension (OLE) trial of PATHFNDR-1, showing paltusotine maintained IGF-1 levels comparable to prior injected SRL therapy for up to 60 weeks. $NBIX Citizens went on to say:
1 · Reply
StocktwitsNews
StocktwitsNews Jul. 14 at 2:41 AM
Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds $CRNX https://stocktwits.com/news/equity/markets/crinetics-pharma-s-oral-drug-shows-lasting-relief-for-acromegaly-patients-in-latest-study-retail-buzz-builds/ch8B1oBR5Nq
1 · Reply
AlertsAndNews
AlertsAndNews Jul. 13 at 10:40 PM
$CRNX Crinetics Reports Long-Term Data for PALSONIFY Showing Sustained IGF-1 Control Crinetics released long-term data from PATHFNDR-1 and PATHFNDR-2 showing PALSONIFY maintained stable IGF-1 levels in open-label extension studies. Additional data showed reductions in patient-reported symptom severity and flare rates. Full results presented at ENDO 2025.
0 · Reply
G101SPM
G101SPM Jul. 11 at 6:45 PM
#SHOWTIME ^ H.C. Wainwright Kidney Virtual Conference (July 14) Scheduled to appear: $AKBA, $UNCY ^ Endocrine Society Meeting (July 14-15) Scheduled to appear: $CRNX, $VCYT
1 · Reply
BlakeCanyon50
BlakeCanyon50 Jul. 11 at 4:25 PM
$ARCT & $CRNX = Took a position in both today. 2,000 ARCT & 1,000 CRNX shares.
0 · Reply
Quantumup
Quantumup Jul. 11 at 3:03 PM
Goldman Sachs, on 7/10,🏁 $NBIX Buy-$182. $CRNX $TAK $BMY Goldman Sachs said in its initiation report:
0 · Reply
RickyGlow
RickyGlow Jul. 9 at 2:28 PM
$CRNX Somebody knows something...easy double from here before the year is over, maybe before the Summer is over!
2 · Reply
Quantumup
Quantumup Jul. 9 at 10:24 AM
UBS⬆️ $NBIX PT to $174 from $152, reiterated Buy and said, "Lot less polarized vs 4Q24 and 1Q25 set-up: we expect outperformance at 2Q" $CRNX $TAK UBS added, "We continue to see steady upside on the stock for remainder of 2025. For the stock to break from the recent range-bound action, we believe consistently strong uptake on Crenessity is key. Based on our incomings, we believe the stock is lot less polarized heading into the 2Q25 print, as opposed to 4Q24 (Crenessity elevated expectations) and 1Q25 (Ingrezza bear case). We are raising our PT to $174 (from $152) based on 5.25x EV/'30E sales (prior 4.5x), supported by a DCF; we increase our multiple to reflect an increasing growth narrative with early bullish indicators for Crenessity launch. Crenessity physician checks indicate 400+ new patient starts realistic in 2Q" UBS went on to say:
0 · Reply
RickyGlow
RickyGlow Jul. 3 at 1:57 PM
$CRNX Anyone not being these three stocks right now - $CRNX $GLXY $ASPI - just doesn't like money!
0 · Reply
Quantumup
Quantumup Jul. 2 at 5:57 PM
Citizens reiterated $CRNX Market Outperform-$90. $NBIX $CORT $IMVT $BBIO ARGX VRDN AMGN TRML RGLS - NVS VRTX Citizens said in its note: "Crinetics ( $CRNX, MO, $90 PT) will present Phase 2 TouCAHn data for atumelnant in congenital adrenal hyperplasia (CAH) during the oral session "All About Congenital Adrenal Hyperplasia and Adrenal Insufficiency" on Saturday, July 12. While the abstract remains embargoed, previously released data show the once-daily oral ACTH antagonist induces rapid and sustained reductions of androstenedione and 17- hydroxyprogesterone over 12 weeks, with most patients normalizing A4 within two weeks (our coverage here). Importantly, atumelnant had greater A4 reductions than Neurocrine's ( $NBIX, NC) approved drug Crenessity, which could translate to greater glucocorticoid (GC) reductions (the regulatory endpoint). $CRNX will also present two posters on reductions in adrenal volume and 11-oxygenated androgens in the Phase 2 trial. Citizens goes on to say:
2 · Reply